Lp(a)-lowering therapies
Lp(a)-lowering therapies has been studied in 1 paper since 2026: none in people yet; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Jul 24, 2026: “Lp(a) testing and treatment with Lp(a)-lowering therapies in the primary and secondary prevention of cardiovascular disease in high income countries: A preliminary health…”.
1 paper studies it1 findingUpdated
See all 1 papers on lp(a)-lowering therapies
- In silico1
What did studies of lp(a)-lowering therapies find?
1Studies of lp(a)-lowering therapies measured 1 outcome; the most studied are cardiovascular disease (1 study).
Cardiovascular disease
downin silico1
1 study
Cardiovascular disease
downin silico1
Lp(a)-lowering therapies decrease cardiovascular disease in silico (simulated in primary prevention population) (53 CV events prevented).
“Lp(a) testing and treatment prevented 53 and 306 CV events in the primary and secondary prevention populations (n=10,000 each), respectively.”
In silicosimulated in primary prevention populationlowered Lp(a) by 97.5%n = 10,000
Atherosclerosis